Altimmune Announces Positive Data for Pemvidutide in Alcohol Use Disorder
Altimmune reported positive topline results from its Phase 2 trial of pemvidutide for alcohol use disorder, showing significant reductions in heavy drinking days and favorable safety. The company plans to discuss these data with the FDA.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day